Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × Calcium Dobesilate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 208 Precursor Cell Lymphoblastic Leukemia-Lymphoma 61 Recurrence 30 Burkitt Lymphoma 29 Leukemia 28 Lymphoma 26 Neoplasms, Plasma Cell 21 Lymphoma, Non-Hodgkin 17 Lymphoma, Mantle-Cell 16 Neoplasms 15 Nausea 15 Vomiting 14 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14 Immunoglobulin Light-chain Amyloidosis 14 Lymphoma, Large B-Cell, Diffuse 12 Hodgkin Disease 12 Breast Neoplasms 12 Waldenstrom Macroglobulinemia 11 Lymphoma, Follicular 10 Lymphoma, B-Cell, Marginal Zone 9 Prostatic Neoplasms 8 Neoplasm Metastasis 8 Leukemia, Myeloid, Acute 8 Leukemia, Biphenotypic, Acute 8 Amyloidosis 8 Smoldering Multiple Myeloma 7 Lung Neoplasms 7 Lymphoma, T-Cell, Cutaneous 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Leukemia, Myelomonocytic, Chronic 5

Interventions

pembrolizumab 256 Nivolumab 228 Ipilimumab 208 Cyclophosphamide 125 aldesleukin 123 Interleukin-2 92 Dacarbazine 68 trametinib 66 Temozolomide 66 fludarabine 64 Vemurafenib 63 dabrafenib 59 fludarabine phosphate 56 Radiosurgery 43 sargramostim 40 Biopsy 40 Bevacizumab 39 binimetinib 38 incomplete Freund's adjuvant 37 Paclitaxel 35 Cisplatin 34 Radiotherapy 33 encorafenib 31 atezolizumab 31 cobimetinib 30 Magnetic Resonance Spectroscopy 30 Carboplatin 29 Introns 28 Specimen Handling 27 CTLA-4 Antigen 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02862145 2016-09-27

MRX34-102

Mirna Therapeutics, Inc.

Phase 1/2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡